摘要
目的:观察阿卡波糖联合二甲双胍对2型糖尿病(T2DM)合并肥胖/超重患者血糖、体质指数及生命质量等指标的影响,评价其临床疗效和安全性。方法:选取2型糖尿病合并肥胖/超重患者106例,按随机数字表法分为观察组和对照组,各53例。对照组给予二甲双胍,观察组在对照组的基础上给予阿卡波糖,比较两组治疗前和治疗后6个月的空腹血糖(FBG)、糖化血红蛋白(HbA1c)、体质指数(BMI)水平、SF-36量表得分及不良反应发生情况。结果:与治疗前相比,治疗后两组的FBG、HbA1c及BMI水平均降低,差异有统计学意义(P<0.05),且观察组低于对照组,差异有统计学意义(P<0.05);治疗后观察组和对照组的SF-36量表得分有一定程度提高,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应率比较,差异无统计学意义(P>0.05)。结论:阿卡波糖联合二甲双胍对改善T2DM合并肥胖/超重患者的血糖、体质指数及生命质量等指标具有较好的效果,没有证据提示联合用药能增加不良反应的发生几率。
Objective To observe the effects of acarbose combined with metformin on blood sugar,body mass index and quality of life in patients with type 2 diabetes mellitus(T2DM)and obesity/overweight,and to evaluate its clinical efficacy and safety.Method 106 patients with T2DM complicated with obesity/overweight were selected.They were divided into observation group and control group according to random number table method,53 cases in each group.The control group was given metformin,while the observation group was given acarbose on the basis of the control group.The levels of fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c),body mass index(BMI),SF-36 score and adverse reactions were compared between the two groups before and 6 months after treatment.Results Compared with before treatment,the levels of FBG,HbA1c and BMI in the control group and the observation group decreased after treatment(P<0.05),and the observation group was lower than the control group(P<0.05);after treatment,the SF-36 scale scores in the observation group and the control group increased to a certain extent,and the observation group was higher than the control group(P<0.05);there was no significant difference in the adverse reaction rate between the two groups(P>0.05).Conclusion Acarbose combined with metformin has a good effect on improving blood sugar,body mass index and quality of life in patients with T2DM and obesity/overweight.At present,there is no evidence that combination of acarbose and metformin can increase the incidence of adverse reactions.
作者
覃芳
蒙春越
QIN Fang;MENG Chun-yue(Department of internal Medicine,Liu zhou Red cross Hospital of Guangxi,Liuzhou 545001,China)
出处
《吉林医学》
CAS
2020年第10期2329-2332,共4页
Jilin Medical Journal
关键词
2型糖尿病
肥胖
阿卡波糖
二甲双胍
联合用药
Type 2 diabetes mellitus
Obesity
Acarbose
Metformin
Combination therapy
